Frontiers in Immunology (Mar 2018)

Novel Platforms for the Development of a Universal Influenza Vaccine

  • Arun Kumar,
  • Arun Kumar,
  • Trine Sundebo Meldgaard,
  • Trine Sundebo Meldgaard,
  • Sylvie Bertholet,
  • Sylvie Bertholet

Journal volume & issue
Vol. 9


Read online

Despite advancements in immunotherapeutic approaches, influenza continues to cause severe illness, particularly among immunocompromised individuals, young children, and elderly adults. Vaccination is the most effective way to reduce rates of morbidity and mortality caused by influenza viruses. Frequent genetic shift and drift among influenza-virus strains with the resultant disparity between circulating and vaccine virus strains limits the effectiveness of the available conventional influenza vaccines. One approach to overcome this limitation is to develop a universal influenza vaccine that could provide protection against all subtypes of influenza viruses. Moreover, the development of a novel or improved universal influenza vaccines may be greatly facilitated by new technologies including virus-like particles, T-cell-inducing peptides and recombinant proteins, synthetic viruses, broadly neutralizing antibodies, and nucleic acid-based vaccines. This review discusses recent scientific advances in the development of next-generation universal influenza vaccines.